May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Zeaxanthin and Atrophic AMD Visual Function Study (ZVF)- Investigator Initiated FDA IND #78,973
Author Affiliations & Notes
  • S. P. Richer
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • W. Stiles
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • K. Graham
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • C. Thomas
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • L. Clouser
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • J. Nyland
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • P. Touzeau
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • J. Bekritsky
    Eye Clinic 112E, DVA Medical Center, North Chicago, Illinois
  • D. Richer
    University of Pennsylvania, Philadelphia, Pennsylvania
  • D. Park
    RFUMS Chicago Medical School, North Chicago, Illinois
  • Footnotes
    Commercial Relationships  S.P. Richer, Chrysantis, Inc, F; Kowa JP, F; Stereo Optical, Inc, F; Pharmanex, Inc, F; ZeaVision, Inc, F; Heidelberg Engineering, F; W. Stiles, None; K. Graham, None; C. Thomas, None; L. Clouser, None; J. Nyland, None; P. Touzeau, None; J. Bekritsky, None; D. Richer, None; D. Park, None.
  • Footnotes
    Support  Chrysantis,Inc (West Chicago, IL)
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4973. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. P. Richer, W. Stiles, K. Graham, C. Thomas, L. Clouser, J. Nyland, P. Touzeau, J. Bekritsky, D. Richer, D. Park; The Zeaxanthin and Atrophic AMD Visual Function Study (ZVF)- Investigator Initiated FDA IND #78,973. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4973. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : In LAST I, II (Optom 2004 75; 4:216-30 & 2007 78; 5: 213-9) we demonstrated that lutein induced macular pigment optical density (MPOD) elevation mirrored visual benefits for patients with age related macular degeneration (AMD) by improving visual symptoms (i.e. better VA, CSF, photostress glare recovery). We now describe the design / baseline data of a randomized, double blind, lutein controlled study of the predominant foveal carotenoid zeaxanthin (Z) on MPOD, visual function, retinal blood flow & neuro-cognitive status in atrophic AMD.

Methods: : A 1 year, 4 visit, prospective, randomized, double blind, both "intention-to-treat" & "per-protocol using only observed data", lutein controlled study of patients with mild and moderate AMD, but not advanced disease. Sample: 60 AMD patients (approx 120 eyes) randomly assigned to one of 2 dietary supplement treatment carotenoid pigment arms (8mg Z; n=25 & 8mg Z / 9mg L; n=25), or to a traditional 9 mg lutein supplement intervention control group (n=10). General Data includes, NEI VFQ25, Harvard Dietary FFI GP88, BMI / % body fat & biophotonic skin carotenoid scan. Non- dilated near refraction data includes SKILL & Colenbrander low contrast VA, 10° kinetic 3 wavelength - 5 contrast Amsler Grid, Foveal QuantifEYE 1° HFF MPOD & an APA administered neuro-cognitive assessment. Non dilated distance refraction data includes EDTRS VA, CSF, 6.5° large letter ChromaTest Tritan/Protan thresholds & Kowa AS14B Photostress Glare Recovery. Dilated Ophthalmic tests include an Image Technologies Autofluorescence 14° 3D MPOD distribution (Sharifzadeh M, Bernstein PS, Gellermann W, J Opt Soc Am 2006 23(10):2373-87), 50° retinal & RPE lipofuscin images, Heidelberg HRF (10° deg x 2.5°) foveal-centered laser doppler nasal/temporal parafoveal sensory retinal blood flow & LOCS III lens classification.

Results: : Baseline demographic, visual function, ocular and neuro- cognitive assessment profiles post randomization are provided.

Conclusions: : Although, the power and time frame of this study are probably insufficient to assess clinical AMD disease progression, our comprehensive data set should provide unique insights about AMD visual function and response to supplemental nutritional carotenoids.

Clinical Trial: : www.clinicaltrials.gov 00564902

Keywords: age-related macular degeneration • macular pigment • carotenoids/carotenoid binding proteins 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×